Novartis just signed a $1.6B buyout pact with a lead player in an emerging anti-inflammatory field

The executive crew at IFM has just racked up their second blockbuster-sized biotech sale in less than two years.

Not long after Bristol-Myers Squibb stepped up with $300 million in cash to ink a $2.3 billion-plus pact on the oncology applications of their work on NLRP3 in the summer of 2017, pharma giant Novartis has lined up rights to the flip side of that coin, paying IFM $310 million upfront in a $1.6 billion bid to demonstrate what NLRP3 can do on the anti-inflammatory side of things.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->